Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia

[1]  Heather D. Huntsman,et al.  Heterodimerization of TPO and IFNγ Impairs Human Hematopoietic Stem/Progenitor Cell Signaling and Survival in Chronic Inflammation , 2017 .

[2]  B. Drénou,et al.  Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia , 2017, Haematologica.

[3]  D. Kaplan.  Persistence of exhaustion in cured hep C. , 2017, Blood.

[4]  B. Dumitriu,et al.  Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia , 2017, The New England journal of medicine.

[5]  Y. Kwong,et al.  The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia , 2017, British journal of haematology.

[6]  C. Jung,et al.  Efficacy and Safety of Romiplostim in Patients with Aplastic Anemia Refractory to Immunosuppressive Therapy: 1-Year Interim Analysis of Phase 2 Clinical Trial , 2016 .

[7]  R. Latour.  Transplantation for bone marrow failure: current issues , 2016 .

[8]  M. Manz,et al.  Enhanced thrombopoietin but not G-CSF receptor stimulation induces self-renewing hematopoietic stem cell divisions in vivo. , 2016, Blood.

[9]  B. Dumitriu,et al.  Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. , 2014, Blood.

[10]  B. Dumitriu,et al.  Eltrombopag and improved hematopoiesis in refractory aplastic anemia. , 2012, The New England journal of medicine.

[11]  V. Plagnol,et al.  Exome sequencing identifies MPL as a causative gene in familial aplastic anemia , 2012, Haematologica.

[12]  N. Young,et al.  Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. , 2011, The New England journal of medicine.

[13]  D. Follmann,et al.  Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. , 2003, JAMA.